Cell division cycle 20 homolog (CDC20) is a well-known regulator of cell cycle progression. Abnormal expression of CDC20 leads to mitotic defects, which play a significant role in cancer development. In breast cancer (BC), CDC20 has been identified as a biomarker that has been linked to poor patient outcomes. In this study, we investigated the association of CDC20 with BC prognosis and immune cell infiltration by using multiple online databases, including UALCAN, KM plotter, TIMER2.0, HPA, TNM-plot, bc-GenExMiner, LinkedOmics, STRING, and GEPIA. The results demonstrate that BC patients have an elevated CDC20 expression in tumor tissues compared with the adjacent normal tissue. In addition, BC patients with overexpressed CDC20 had a median survival of 63.6 months compared to 169.2 months in patients with low CDC20 expression. Prognostic analysis of the examined data indicated that elevated expression of CDC20 was associated with poor prognosis and a reduction of overall survival in BC patients. These findings were even more prevalent in chemoresistance triple-negative breast cancer (TNBC) patients. Furthermore, the Gene Set Enrichment Analysis tool indicated that CDC20 regulates BC cells’ cell cycle and apoptosis. CDC20 also significantly correlates with increased infiltrating B cells, CD4+ T cells, neutrophils, and dendritic cells in BC. In conclusion, the findings of this study suggest that CDC20 may be involved in immunomodulating the tumor microenvironment and provide evidence that CDC20 inhibition may serve as a potential therapeutic approach for the treatment of BC patients. In addition, the data indicates that CDC20 can be a reliable prognostic biomarker for BC.
细胞分裂周期蛋白20同源物（CDC20）是细胞周期进程的关键调控因子。其异常表达会导致有丝分裂缺陷，在癌症发展中起重要作用。在乳腺癌中，CDC20已被确定为与不良预后相关的生物标志物。本研究通过整合UALCAN、KM plotter、TIMER2.0、HPA、TNM-plot、bc-GenExMiner、LinkedOmics、STRING及GEPIA等多个在线数据库，系统分析了CDC20与乳腺癌预后及免疫细胞浸润的关联。结果显示：与癌旁正常组织相比，乳腺癌组织中CDC20表达显著升高；高表达CDC20患者中位生存期为63.6个月，显著低于低表达组的169.2个月。预后分析表明CDC20高表达与患者不良预后及总生存期缩短密切相关，这种现象在化疗耐药的三阴性乳腺癌患者中尤为突出。基因集富集分析提示CDC20参与调控乳腺癌细胞的细胞周期与凋亡进程。同时，CDC20表达水平与肿瘤浸润B细胞、CD4+ T细胞、中性粒细胞及树突状细胞的富集程度呈显著正相关。本研究证实CDC20可能通过调控肿瘤微环境参与免疫调节，其抑制剂有望成为乳腺癌治疗的新策略，同时CDC20可作为可靠的乳腺癌预后生物标志物。
Prognostic and Therapeutic Implications of Cell Division Cycle 20 Homolog in Breast Cancer
肿瘤(癌症)患者之家